“The true value of IP protection is in its ability to ensure that critical research reaches the market”

Bryan spent eight years in cutting-edge translational research. His diverse experience spans recording electrical nanocurrents from a single brain cell to drafting randomized clinical trial protocols. In 2016, he was made a Churchill Fellow (CF) for his outstanding achievements in the biomedical field.

Initially at the Florey Institute of Neuroscience & Mental Health and then at the Hudson Institute of Medical Research, Bryan’s passion has been driven by a simple phrase – ‘from bench to bedside’. “How can we advance laboratory findings to tangible products that can save lives?” Bryan completed his PhD in Neuroscience studying childhood genetic epilepsies, identifying a distinct disease pathway and a potential novel treatment for Dravet syndrome. 

Bryan has Australian and international expertise in drafting and prosecuting patents for a range of inventions from breakthrough anti-cancer drugs, CAR-T therapies, anti-inflammatory compositions, embryonic stem cells, to modified clinical dosage regimes for pharmaceuticals. 

Bryan has experience in patent searching and landscape mapping, using comprehensive mapping software to provide insights on both existing and emerging competitors. He has also prepared due diligence reports for venture capital investors and general advice to clients for use in investors updates to the share market. Bryan’s work has been published in highly prestigious journals ranked top of their field, including Brain and the Journal of Clinical Investigation.

Qualifications

  • PhD (Neuroscience) - The University of Melbourne
  • Bachelor of Biomedical Science - The University of Melbourne
  • Bachelor of Science (Honours) - The University of Melbourne